Status:
COMPLETED
Safety and Efficacy of Seroquel in First Episode Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-35 years
Phase:
PHASE4
Brief Summary
To compare the safety, tolerability and efficacy of Seroquel and risperidone in first episode schizophrenia
Eligibility Criteria
Inclusion
- Age 18-35 years Meet ICD-10 criteria for schizophrenia No abnormaility on clinical examination No previous episode of psychosis No previous antipsychotics of any kind in last 3 months
Exclusion
- Have received a course of antipsychotics drug treatment prior to entry which may introduce risk factors or interfere with study procedures Have received anticholinergics within 10 days of baseline aseessment Have received mood stabilizers or anti depressants within 2 weeks
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00254241
Start Date
May 1 2002
End Date
June 1 2006
Last Update
June 11 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom